Search
Close this search box.

Genomics and New Medicine Discovery

We deliver actionable policy to support these evolving sectors in the UK and offer broader policy insights into related areas of global focus

Why is this important?

New treatments such as cell and gene therapy hold immense promise and will increasingly inform strategies for addressing global public health threats, both in the short and long-term. However, governments and system leaders must work to ensure that the transformational benefits of genomics and new medicines are felt equally across the world.

What we do

We deliver actionable policy to support these evolving sectors in the UK and offer broader policy insights into related areas of global focus.

What are the benefits?

Recent years have witnessed rapid advances in the treatment of infectious and rare diseases, and genomic science lays at the heart of much of this progress.

Sharing these advances fairly will help to create a more resilient and equal world, ensuring that genomics-based healthcare interventions can be accessed by all, for the benefit of all.

Featured Content

Equity of Access and Return in Global Genomics

PPP's 2022 global genomics report and series was chaired by Kate Orviss, Senior Adviser (Global Genomics) and supported by Mark Bale, Senior Adviser (Genomics), Anna Dickinson, former Senior Policy Analyst, Isla O’Connor, Genomics Programme Adviser and Grace Girling, former Policy Coordinator. The contents of the report was based on over 9 hours of discussion amongst over 100 participants from more than 20 countries drawn from researchers and research institutes, industry (in its many guises), national and international genomics initiatives, clinicians, ethicists and members of the diplomatic community and reflects the truly global reach of genomics.

Implementing precision medicine in the UK: The case of cancer vaccines

Written by Mary Brown, Chaired by Dr Lennard Lee and Dr Joanne Hackett

Personalised neoantigen cancer vaccines potentially represent the next paradigm shift in precision treatment for cancer patients. Given that research into cancer vaccines is at an early stage, the UK is well-placed to utilise its competitive advantage to attract investment. This includes the experience of running some of the fastest recruiting pandemic vaccines studies, its outstanding genomic capabilities and research talent and experience.

PPP programmes in this area

PPP convenes public sector leaders and key stakeholders to discuss practical application of policy in the following related topics:

Scroll to Top